Nature Med. 5, 1052– 1056 (1999).
On page 1052, the last two column headings in Table 1 lacked the correct superscripting. The correct column headings are "particles/mla" and A20+capsids/mlb." On page 1053, the column headings for Table 2 were shifted. The correct table is printed below.
We regret these errors.
Author information
Authors and Affiliations
Additional information
The online version of the original article can be found at 10.1038/12491
Rights and permissions
About this article
Cite this article
Girod, A., Ried, M., Wobus, C. et al. Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5, 1438 (1999). https://doi.org/10.1038/71021
Issue Date:
DOI: https://doi.org/10.1038/71021
This article is cited by
-
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Journal of Neurodevelopmental Disorders (2018)
-
Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering
Journal of Biomedical Science (2014)
-
Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy
Scientific Reports (2014)
-
Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides
Molecular Therapy - Methods & Clinical Development (2014)
-
Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy
Molecular Therapy (2014)
